Related Experiment Video

Updated: Jun 5, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

[Gefitinib molecular target therapy for Chinese patients with non-small cell lung cancer]

Yilong Wu1, Xuening Yang, Jinji Yang

  • 1The Lung Cancer Research Institute and Cancer Center, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, P.R.China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|January 19, 2011
PubMed
Abstract

Insights

Gefitinib is a safe and effective molecular targeted therapy for Chinese patients with advanced non-small cell lung cancer (NSCLC). This study found good response and disease control rates with no severe side effects observed.

Area of Science:

  • Oncology
  • Molecular Therapy
  • Pharmacology

Context:

  • Non-small cell lung cancer (NSCLC) is a significant health concern in China.
  • Molecular targeted therapy offers a promising treatment avenue for NSCLC.
  • Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

Purpose:

  • To evaluate the clinical experience and outcomes of gefitinib therapy in Chinese patients with advanced NSCLC.
  • To assess the efficacy and safety profile of gefitinib in a real-world setting.

Summary:

  • A retrospective analysis of 282 Chinese patients with advanced NSCLC treated with gefitinib between July 2001 and December 2003.
  • Observed response rates ranged from 22.2% to 47.7%, with disease control rates between 62.6% and 81.8%.
  • No severe adverse events were reported during the study period.

Impact:

  • Gefitinib demonstrates favorable safety and efficacy in Chinese patients with advanced NSCLC.
  • Supports the use of gefitinib as a valuable treatment option for this patient population.
  • Provides real-world data on gefitinib's performance in a specific ethnic group.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...